2021

  • Maucort, C., Vo, D.D., Aouad, S., Charrat, C., Azoulay, S., Di Giorgio, A., Duca, M.* Design and implementation of synthetic RNA binders for the inhibition of miR-21 biogenesis. ACS Med. Chem. Lett. 2021 doi.org/10.1021/acsmedchemlett.0c00682
  • Maucort C, Di Giorgio A, Azoulay S, Duca M.* Differentiation of Cancer Stem Cells by Using Synthetic Small Molecules: Toward New Therapeutic Strategies against Therapy Resistance. ChemMedChem 2021 doi: 10.1002/cmdc.202000251

2020

Di Giorgio A., Duca M.* New Chemical Modalities Enabling Specific RNA Targeting and Degradation: Application to SARS-CoV-2 RNA. ACS Cent. Sci. 2020 6, 1647

Aradi K., Di Giorgio A., Duca M.* Recent progresses in aminoglycoside conjugation for RNA targeting: antimicrobials and beyond. Eur. J. 2020 26, 12273

Signetti L., Elizarov N., Simsir M., Paquet A., Douguet D., Labbal F., Debayle D., Di Giorgio A., Biou V., Girard C., Duca M., Bretillon L., Bertolotto C., Verrier B., Azoulay S., Mus-Veteau I. Inhibition of Patched Drug Efflux Increases Vemurafenib Effectiveness against Resistant BrafV600E Melanoma. Cancers 2020 12, 1500

Martin C., De Piccoli S., Gaysinski M., Becquart C., Azoulay S., Di Giorgio A., Duca M.* Unveiling RNA Binding Properties of Verapamil and Preparation of New Derivatives as Inhibitors of HIV-1 Tat-TAR Interaction. ChemPlusChem 2020 85, 207

2019

  • Joly, J.P., Gaysinski, M., Zara, L., Duca, M., Benhida, R. Functionalized C-nucleosides as remarkable RNA binders: targeting of prokaryotic ribosomal A-site RNA. Chem. Commun. 2019 55, 10432.

  • A. Di Giorgio, M. Duca Synthetic small-molecule RNA ligands: future prospects as therapeutic agents MedChemComm 2019 10, 1242.

2018

  • C. Becquart, M. Le Roch, S. Azoulay, P. Uriac, A. Di Giorgio, M. Duca Exploring heterocycle-spermine conjugates as modulators of oncogenic microRNAs biogenesis ACS Omega 2018 3, 16500.

  • Vo, D.D., Becquart, C., Tran, T.P.A., Di Giorgio, A., Darfeuille, F., Staedel, C., Duca, M. Building of neomycin-nucleobase-aminoacid conjugates for the inhibition of oncogenic microRNAs biogenesis Org. Biomol. Chem. 2018 16, 6262.
  • Staedel, C., Tran, T.P.A., Giraud, J., Darfeuille, F., Di Giorgio, A., Tourasse, N.J., Salin, F., Uriac, P., Duca, M. Modulation of oncogenic miRNA biogenesis using functionalized polyamines Scientific Reports 2018 8, 1667.

2017

  • Vo, D.D., Duca, M. Design of multimodal small molecules targeting miRNAs biogenesis : synthesis and in vitro evaluation Methods Mol. Biol.2017 1517, 137.
  • Duca, M. Interfering with Enzymatic steps of microRNAs pathway using small molecules in Advances in Studies on Enzyme Inhibitors as Drugs Ed. Novascience 2017 vol.1, p.83.

2016

  • D.D. Vo, T.P.A. Tran, C. Staedel, R. Benhida, A. Di Giorgio, M. Duca Oncogenic microRNAs biogenesis as a drug target : structure-activity relationship studies on novel aminoglycoside conjugates Chem. Eur. J. 2016 22, 5350-5362.
  • A. Di Giorgio, T. P. A. Tran, M. Duca Small-molecule approaches toward the targeting of oncogenic microRNAs : roadmap for the discovery of RNA modulators, Future Med. Chem. 2016 8, 803-816.

2015

  • T.P.A. Tran, D.D. Vo, A. Di Giorgio, M. Duca Ribosome-targeting antibiotics as inhibitors of oncogenic microRNAs biogenesis : Old scaffolds for new perspectives in RNA targeting. Bioorg. Med. Chem. 2015 23, 5334-5344
  • L. Pascale, A. López González, A. Di Giorgio, M. Gaysinski, J. Teixido Closa, R. Estrada Tejedor, S. Azoulay, N. Patino Deciphering structure-activity relationships in a series of Tat/TAR inhibitors. J. Biomol. Struct. Dyn. 2015

2014

  • D.D. Vo, C. Staedel, L. Zehnacker, R. Benhida, F. Darfeuille, M. Duca Targeting the production of oncogenic microRNAs with multimodal synthetic small molecules. ACS Chem. Biol. 2014  9, 711-21.
  • J.P. Joly, G. Mata, P. Eldin, L. Briant, F. Fontaine-Vive, M. Duca, R. Benhida Artificial nucleobase-amino acid conjugates : a new class of TAR RNA binding agents. Chem Eur. J. 2014 20, 2071-9
  • Rocchi S., Ballotti R., Benhida R., Cerezo M., Duca M., Joly, J.P. Preparation of arylsulfonamido thiazole derivs. as antitumor agents PCT Int. Appl. (2014), WO 2014072486

2013

  • L. Pascale, S. Azoulay, A. Di Giorgio, L. Zenacker, M. Gaysinski, P. Clayette, N. Patino (2013). Thermodynamic studies of a series of homologous HIV-1 TAR RNA ligands reveal that loose binders are stronger Tat competitors than tight ones. Nucleic Acids Res 11, 5851.
  • C.Y. Darini, P. Martin, S. Azoulay, M.D. Drici, P. Hofman, S. Obba, C. Dani, A. Ladoux (2013). Targeting cancer stem cells expressing an embryonic signature with anti-proteases to decrease their tumor potential. Cell Death Dis 4, E706

2012

  • P. Vekhoff, M. Duca, D. Guianvarc’h, R. Benhida, P.B. Arimondo (2012). Sequence specific base pair mimics are efficient topoisomerase IB inhibitors. Biochemistry, 51, 43-51.
  • G. Upert, A. Di Giorgio, A. Upadhyay, D. Manvar, N. Pandey, V.N. Pandey, N. Patino (2012). Inhibition of HIV Replication by Cyclic and Hairpin PNAs Targeting the HIV-1 TAR RNA Loop. J Nucleic Acids
  • V. Malnuit, M. Duca, R. Benhida (2011). Targeting DNA base pair mismatch with artificial nucleobases. Advances and perspectives in triple helix strategy. Org. Biomol. Chem., 9, 326-36.